Publications 2022-23

59. Kumar V, Wahane A, Gupta A, Manautou JE, Bahal R. Multivalent Lactobionic acid and N-Acetylgalactosamine-conjugated Peptide Nucleic Acids for Efficient in vivo Targeting of Hepatocytes“. Advanced Healthcare Materials (Accepted)2023.

58. Wang Y#, Malik S#, Suh HW, Xiao Y, Deng Y, Fan R, Huttner A, Bindra RS, Singh V, Saltzman WM*, Bahal R*. “Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy”. Science Advances (Accepted)2023. #Both authors contributed equally, *co-corresponding senior authors.

57. Ahangari F, Price NL, Malik S, Chioccioli M, Bärnthaler T, Adams TS, Kim J, Pradeep SP, Ding S, Cosme Jr C, Rose K, McDonough J, Aurelien N, Ibarra G, Omote N, Schupp JC, DeIuliis G, Villalba JA, Sharma L, Ryu C, Dela Cruz C, Liu X, Prasse A, Rosas I, Bahal R, Fernandez-Hernando C, Kaminski N. “microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis“. JCI Insight (Accepted), 2023.

56. Putman R, Ricciardi AS, Carufe K, Quijano E, Bahal R, Glazer PM, Saltzman MW. “Nanoparticle-mediated genome editing in single-cell embryos via peptide nucleic acids“. Bioengineering & Translational Medicine, 2022.

55. Wu H, Wahane A, Alhamadani F, Zhang K, Parikh R, Lee S, McCabe EM, Rasmussen TP, Bahal R, Zhong X, Manautou JE. Nephrotoxicity of Antisense Oligonucleotide Drugs“. Current Opinion in Toxicology, 2022.

54. Emehiser RG,  Dhuri K,  Shepard C,  Karmakar S,  Bahal R, Hrdlicka PJ. Serine-γPNA, Invader probes and chimeras thereof: Three probe chemistries enabling sequence-unrestricted recognition of double-stranded DNA“. Organic & Biomolecular Chemistry, 2022.

53. Liu A, Zhao J, Shah M, Migliorati J, Tawfik S, Bahal R, Rasmussen T, Manautou J, Zhong X. “Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies“. ACS Pharmacology & Translational Science, 2022. 

52. Dhuri K, Pradeep SP, Shi J, Anastasiadou E, Slack FJ, Gupta A, Zhong X, Bahal R. “Simultaneous targeting of multiple oncomiRs with phosphorothioate or PNA-based anti-miRs in lymphoma cell lines“. Pharmaceutical Research, 2022.

51. Zhang X, Rotllan N, CanfránDuque A, Sun J, Toczek J, Moshnikova A, Malik S, Price NL, Araldi E, Zhong W, Sadeghi MM, Andreev OA, Bahal R, Reshetnyak YK, Suárez Y, Fernández-Hernando C. “Targeted Suppression of miRNA-33 Using pHLIP Improves Atherosclerosis Regression“. Circulation Research, 2022.

50. Edalatian Zakeri S#, Pradeep SP#, Kasina K#, Laddha AP, Manautou JE, Bahal R. “Casimersen for the treatment of Duchenne Muscular Dystrophy“. Trends in Pharmacological Sciences, 2022. #authors contributed equally.

49. Jin Y, Edalatian Zakeri S, Bahal R, Wiemer AJ.New Technologies Bloom Together for Bettering Cancer Drug Conjugates“. Pharmacological Reviews, 2022.

48. Kasina V, Mownn RJ, Bahal R, Sartor GC. Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology, 2022.

47. Migliorati J, Liu S, Liu A, Gogate A, Nair S, Bahal R, Rasmussen T, Manautou J, Zhong X.Absorption, distribution, metabolism, and excretion of FDA-approved antisense oligonucleotide drugs.Drug Metabolism and Disposition, 2022.

46. Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen T, Bahal R, Zhong X, Manautou J. Adverse Drug Reactions and Toxicity of the FDA-approved Antisense Oligonucleotide Drugs. Drug Metabolism and Disposition, 2022.

45. Dhuri K#, Gaddam R#, Kim YR, Jacobs J, Kumar V, Li Q, Irani K, Bahal R*, Vikram A*. γ peptide nucleic acid-based miR-122 inhibition rescues vascular endothelial dysfunction in mice fed a high-fat diet. Journal of Medicinal Chemistry, 2022. #Both authors contributed equally, *co-corresponding senior authors